News & Events
January 11, 2022
DiMe Journal Club features Critical Path for Parkinson’s 3DT initiative
Join 3DT and DiMe Society, January 11, to hear about 3DT recommendations for patient engagement.
C-Path’s Critical Path for Parkinson’s is excited to announce that on Tuesday, January 11 (11 a.m. ET), the Digital Medicine Society’s Virtual Journal Club will feature key findings and answer questions on 3DT’s (Digital Drug Development Tools) recommendations for involving people with Parkinson’s in clinical studies using digital health tools.
September 17, 2021 - September 23, 2022
Movement Disorders Congress 2021 | Presentations on behalf of CPPCritical Path for Parkinson’s members, advisors and staff submitted six posters on behalf of CPP and CPP’s digital effort, Digital Drug Development Tools (3DT), to MDS Virtual Congress 2021. All abstracts are available here. Data Driven Paths to Advancing Precision Medicine Strategies for Parkinson’s Disease: Critical Path for Parkinson’s Consortium (abstract #341) Martijn Muller1,......
August 17, 2021
View Now | C-Path Neuroscience Program Webinar – NfL in Neurodegenerative Diseases
C-Path’s Neuroscience Program hosted its first webinar on August 17, 2021. This webinar brought together more than 330 members, representatives and partners from pharmaceutical industries, academic experts, government and regulatory agencies, and patient advocacy groups.
June 6, 2018 - June 7, 2018
Third Annual CPP Member Meeting 2018The third annual CPP Member Meeting (June 6-7, 2018 in London, UK) provided a face-to-face forum for industry, regulators, academic experts and advocacy organizations to collaborate towards the development of Parkinson’s disease therapies. This meeting provided a unique opportunity for stakeholders to celebrate the successes of the consortium to date and align on future options......
June 12, 2017
Critical Path for Parkinson’s Consortium 2017 Annual MeetingThe Critical Path for Parkinson’s (CPP) Consortium, cofounded by C-Path and Parkinson’s UK, held its second annual consortium member meeting on June 12 in Bethesda, MD. The meeting brought together scientists from the biopharmaceutical industry, academic institutions, and government agencies; people living with Parkinson’s; patient-advocacy associations; and U.S. Food and Drug Administration regulators to align on the......